Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Kunheng Pharma-Tech Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload involves 1 distinct examiner and 1 distinct art unit. Such a concentrated profile suggests that the company's current patenting activity is focused on a specific technical advancement within its field. This centralized prosecution allows for a direct engagement with the 1 pending office action. Practitioners can observe that the company's current interactions with the patent office are limited to these specific parameters.
The busiest examiner for this company is HEITMEIER, KENDALL NICOLE, who is overseeing 1 pending office action. Since the busiest examiner pending count is 1, this individual is responsible for the company's active prosecution. The outcome of the company's current efforts depends on the review process within this 1 art unit. Practitioners should analyze the specific tendencies of the 1 distinct examiner to effectively address the 1 pending office action currently on the docket. This focus allows for an analysis of the examiner's past actions and the art unit's requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | HEITMEIER, KENDALL NICOLE | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | HEITMEIER, KENDALL NICOLE | 26d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | HEITMEIER, KENDALL NICOLE | 1621 | §102§103Other | Final Rejection | 26d | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial